What a ChondroFiller injection costs at a private clinic

For most patients, the headline figure to hold in mind is £3,000. That is the guide cost for a single-box ChondroFiller injection at London Cartilage Clinic on Harley Street — the UK's certified delivery centre for the treatment — and it covers the majority of people presenting with a single focal cartilage defect.

The full pricing structure follows a tiered model based on defect size, determined by MRI and real-time ultrasound assessment rather than chosen in advance by the patient:

• One box (defects up to ~3 cm²): approximately £3,000
• Two boxes (defects up to ~4.5 cm²): approximately £5,500
• Three boxes (defects up to ~6 cm²): approximately £8,000
• Complex or multi-compartment presentations: up to approximately £9,800

Each tier is an all-inclusive outpatient package price. The fee covers the initial consultation, real-time ultrasound guidance, the ChondroFiller implant itself, intravenous antibiotic cover during the procedure, and a six-week clinical follow-up — not a bare procedure charge with additional costs added later.

All figures above are guide costs published by the London Cartilage Clinic and should be confirmed directly with the clinic before booking. Because London Cartilage Clinic is currently the only UK certified centre offering this pathway, regional variation in pricing does not apply — patients across the UK travel to the Harley Street site for treatment.

What the package price actually covers

The dominant cost component is the ChondroFiller implant itself. Manufactured by Meidrix Biomedicals GmbH in Germany, it carries CE marking as a Class III medical device — the highest-risk category under European device regulation, reflecting the implant's active biological role in recruiting the patient's own progenitor cells rather than simply filling space. The manufacturing standards, quality controls, and regulatory pathway required to bring a Class III device to market are materially more demanding than those governing standard intra-articular injections such as hyaluronic acid or corticosteroids, and that distinction is the primary reason the price sits at a different order of magnitude.

The package price wraps the implant together with the clinical services needed to deliver it safely: specialist consultation, real-time ultrasound guidance, IV antibiotic cover, and a six-week follow-up. None of those components are charged separately.

Patients comparing quotes should check whether an alternative figure itemises the implant cost separately from the procedural fee. A lower headline number that excludes the implant is not a like-for-like comparison — the implant is where most of the cost lives.

Why the NHS does not routinely offer it

ChondroFiller is not available anywhere in the UK on the NHS. No NICE health technology appraisal exists for the product, which places it entirely outside NHS commissioning frameworks in England, Scotland, Wales, and Northern Ireland. GPs have no referral route into a ChondroFiller pathway — there is no funded channel through which to access it via the health service.

The reason is structural rather than clinical. The NHS commissions treatments that have completed a formal NICE evaluation; ChondroFiller has not yet been evaluated in that way. The absence of an appraisal reflects a maturing evidence base, not any finding on the product's safety or efficacy.

For patients wanting to understand the NHS landscape for cartilage repair, autologous chondrocyte implantation (ACI) has been commissioned by NHS England since 2017 and remains the only biological cartilage cell therapy routinely funded through the health service. Spherox, a cell-based autologous product, is also available at a small number of select NHS trusts, including the Royal Orthopaedic Hospital in Birmingham. Both are surgical procedures — not a direct comparison for the outpatient injection pathway ChondroFiller represents.

Individual Funding Requests, the NHS's exceptional-circumstances mechanism, are sometimes raised as a potential route. In practice, no confirmed precedent for a successful ChondroFiller IFR has been published, and building a treatment plan around that possibility would be unwise. Access to ChondroFiller injection currently means private care.

Whether private medical insurance will cover it

The first practical step for any patient considering private medical insurance is to obtain written pre-authorisation from the insurer before any clinical contact, citing the two relevant CCSD billing codes explicitly: W3111 (cartilage regeneration with collagen scaffold) and W8500 (listed in insurer systems under arthroscopy). W8500 is an administrative billing designation, and some insurers query it and request clarification — it is worth stating in the pre-authorisation request that the current service pathway at London Cartilage Clinic is an ultrasound-guided outpatient injection rather than an arthroscopic procedure, as this can prevent unnecessary delays to a claim.

Bupa, Aviva, and WPA are the insurers most commonly reported to approve these codes, though approval depends on the individual policy, its annual limits, and the clinical details submitted. Naming any of those three insurers is not a guarantee of cover.

The risk that most often surprises patients is partial cover. Some policies will pay the surgeon's fee while explicitly excluding the physical implant. Given that the implant accounts for the majority of the package cost, a policy structured that way may leave most of the total price as an out-of-pocket liability despite the patient believing the treatment to be covered.

If pre-authorisation is declined or the insurer confirms an implant exclusion, the practical routes are full self-funding at the published tier price, or asking the treating clinician at London Cartilage Clinic to provide supporting clinical documentation for an insurer appeal.

How combination pathways change the cost

Certain clinical presentations call for more than a single injectable product, and when that happens the cost structure shifts accordingly.

When ChondroFiller injection is used alongside Arthrosamid — a polyacrylamide hydrogel — the combined package sits at approximately £6,000. The two products are doing entirely different jobs. ChondroFiller is the regenerative scaffold component: it gels in the defect and supports acellular matrix-induced chondrogenesis, recruiting the patient's own progenitor cells to build new tissue. Arthrosamid is a non-regenerative hydrogel that works on joint-space symptoms through a separate mechanism. They are not variants of the same therapy, and the higher price reflects two distinct clinical interventions rather than an upgraded version of one.

A further step up — pairing ChondroFiller injection with autologous mesenchymal stem cells (MSCs) in what is termed a Tri-Active pathway — carries a guide cost of approximately £11,000. The additional cost reflects the biological preparation required to harvest, process, and administer the patient's own cells alongside the scaffold.

Neither combination pathway is the standard route. Both are considered where the clinical picture involves more than a discrete focal defect — for instance, where joint-space factors or biological reserve warrant a broader approach. A consultant assessment at London Cartilage Clinic determines whether a single-product or combination approach is appropriate for the individual presentation.

Where to access ChondroFiller injection in London

For London and commuter-belt patients, the access route is straightforward: Liquid Cartilage™ is delivered in the UK at the London Cartilage Clinic on Harley Street.

Professor Paul Y. F. Lee introduced the ChondroFiller injection technique to UK practice and leads the clinic's ICRS Teaching Centre of Excellence. Technique sensitivity matters with a product of this kind — the same scaffold can produce meaningfully different outcomes depending on how it is applied and by whom.

The starting point is a clinical assessment, not a procedure booking. That consultation establishes whether a focal defect is suitable for the injection pathway, what imaging is needed to characterise it, and whether a single-product or combination approach fits the clinical picture. Useful things to clarify at that first appointment include whether a qualifying insurer policy is in place, whether pre-authorisation should be sought before any further steps, and what the realistic recovery expectations are for the specific joint and defect involved.

To book an assessment, visit londoncartilage.com.